aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.99−0.25 (-4.77%)
Close on Nov 17, 2026Market cap $489.46MP/E –Yield –
aTYR PHARMA r&d expenses
Research and development expenses are spending on new products and technology.
aTYR PHARMA's R&D Expenses for the twelve months ending Jun 30, 2026 was $47.09M, down 13.2% year over year. For fiscal 2025 it was $60.22M, up 10.8% from the year before. Over ten years it grew 5.7% a year on average. The highest annual figure on record is $60.22M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.22M | +10.8% |
| FY2024 | Dec 31, 2024 | $54.37M | +28.6% |
| FY2023 | Dec 31, 2023 | $42.29M | -1.2% |
| FY2022 | Dec 31, 2022 | $42.81M | +84.0% |
| FY2021 | Dec 31, 2021 | $23.26M | +34.5% |
| FY2020 | Dec 31, 2020 | $17.29M | +23.1% |
| FY2019 | Dec 31, 2019 | $14.05M | -31.1% |
| FY2018 | Dec 31, 2018 | $20.39M | -32.2% |
| FY2017 | Dec 31, 2017 | $30.07M | -29.8% |
| FY2016 | Dec 31, 2016 | $42.85M | +24.2% |
| FY2015 | Dec 31, 2015 | $34.50M | +105.7% |
| FY2014 | Dec 31, 2014 | $16.78M | +21.3% |
| FY2013 | Dec 31, 2013 | $13.83M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.75M | -56.1% |
| Q1 FY2026 | Mar 31, 2026 | $7.32M | -38.1% |
| Q4 FY2025 | Dec 31, 2025 | $10.89M | -10.9% |
| Q3 FY2025 | Sep 30, 2025 | $22.13M | +49.5% |
| Q2 FY2025 | Jun 30, 2025 | $15.38M | +10.1% |
| Q1 FY2025 | Mar 31, 2025 | $11.81M | -11.6% |
| Q4 FY2024 | Dec 31, 2024 | $12.23M | -4.1% |
| Q3 FY2024 | Sep 30, 2024 | $14.81M | +43.5% |
| Q2 FY2024 | Jun 30, 2024 | $13.97M | +42.0% |
| Q1 FY2024 | Mar 31, 2024 | $13.36M | +42.5% |
| Q4 FY2023 | Dec 31, 2023 | $12.76M | -14.5% |
| Q3 FY2023 | Sep 30, 2023 | $10.32M | +4.6% |
| Q2 FY2023 | Jun 30, 2023 | $9.84M | +7.7% |
| Q1 FY2023 | Mar 31, 2023 | $9.38M | +5.4% |
| Q4 FY2022 | Dec 31, 2022 | $14.91M | +150.4% |
| Q3 FY2022 | Sep 30, 2022 | $9.87M | +92.0% |
| Q2 FY2022 | Jun 30, 2022 | $9.14M | +19.3% |
| Q1 FY2022 | Mar 31, 2022 | $8.90M | +97.0% |
| Q4 FY2021 | Dec 31, 2021 | $5.96M | +26.8% |
| Q3 FY2021 | Sep 30, 2021 | $5.14M | +11.3% |
| Q2 FY2021 | Jun 30, 2021 | $7.66M | +75.5% |
| Q1 FY2021 | Mar 31, 2021 | $4.52M | +24.9% |
| Q4 FY2020 | Dec 31, 2020 | $4.70M | +30.9% |
| Q3 FY2020 | Sep 30, 2020 | $4.62M | +21.5% |
| Q2 FY2020 | Jun 30, 2020 | $4.36M | +31.6% |
| Q1 FY2020 | Mar 31, 2020 | $3.62M | +8.1% |
| Q4 FY2019 | Dec 31, 2019 | $3.59M | +1.2% |
| Q3 FY2019 | Sep 30, 2019 | $3.80M | -9.6% |
| Q2 FY2019 | Jun 30, 2019 | $3.31M | -48.9% |
| Q1 FY2019 | Mar 31, 2019 | $3.35M | -45.6% |
| Q4 FY2018 | Dec 31, 2018 | $3.55M | -33.2% |
| Q3 FY2018 | Sep 30, 2018 | $4.20M | -41.1% |
| Q2 FY2018 | Jun 30, 2018 | $6.48M | -23.0% |
| Q1 FY2018 | Mar 31, 2018 | $6.15M | -33.2% |
| Q4 FY2017 | Dec 31, 2017 | $5.31M | -41.9% |
| Q3 FY2017 | Sep 30, 2017 | $7.13M | -31.4% |
| Q2 FY2017 | Jun 30, 2017 | $8.42M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.14M | – |
| Q3 FY2016 | Sep 30, 2016 | $10.40M | – |
See a number that looks wrong?